why choose us

First received: November 13, 2022

Clinical Trial: Study to Compare the Efficacy and Safety of ATGC-110 (Botulinum Toxin) With Xeomin® for the Treatment of Moderate to Severe Glabellar Frown Lines

Study Status: Active, not recruiting

Recruit Status: Active, not recruiting

Condition: Glabellar Frown Lines

Study Type: Interventional


Official Title: A Randomized, Double-Blind, Active-Control, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of "ATGC-110" Compared to "Xeomin®" in Patients Who Need Moderate or Severe Glabellar Line Im

Brief Summary: Efficacy and safety of the investigational product, ATGC-110, was evaluated in comparison with Xeomin for a total of 16 weeks after the administration in treatment of glabellar frown lines.

Read more